Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Apr 19, 2026, 15:59Nour Al-Mozain: Why Stem Cell Collection Parameters Need Adjustment in SCD for Gene Therapy?
-
Apr 19, 2026, 15:42S. Kate Hartman: A Clinical Framework for Anemia, Bleeding, and Transfusion Decision-Making
-
Apr 19, 2026, 15:20CHAMPION-AF Demonstrated Better Freedom From Clinically Relevant Bleeding Events – Boston Scientific Cardiology
-
Apr 19, 2026, 14:37Jean-Jacques Mourad: Cohort Study Insights on Aspirin Use in Patients with Horton’s Disease
-
Apr 19, 2026, 14:36Francisco Ujueta: Pulmonary Embolism Care Doesn’t End at the Acute Phase
-
Apr 19, 2026, 14:35Flora Peyvandi: Marking the Beginning of a Future with Less Suffering on World Haemophilia Day
-
Apr 19, 2026, 14:34Chokri Ben Lamine: 50 High-Yield Pearls on Hemoglobin Cutoffs for Anaemia from WHO 2024 Guideline
-
Apr 19, 2026, 14:31Kate Iyore: Simple Explanation of Deep Vein Thrombosis and Pulmonary Embolism
-
Apr 19, 2026, 14:08Emily Smith: From Personal Experience to Global Advocacy on World Haemophilia Day